W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies
X

Meeting of the Transparency Council 8/2023 on 20 February 2023 – UPDATE

The agenda includes:

Preparation of an opinion on the legitimacy of introducing amendments to the “Prenatal testing programme”.

Preparation of positions on the evaluation of medicines:

  • Saphnelo (anifrolumab) under the drug programme “Treatment of patients with active systemic lupus erythematosus (SLE) (ICD 10: M32)”,
  • Glypvilo (vildagliptin) for the indication: treatment of type 2 diabetes mellitus,
  • Keytruda (pembrolizumab) under the drug programme “Follow-up treatment of patients with renal cell carcinoma (ICD-10 C64)”.

Preparation of a position  on the legitimacy of granting reimbursement approvals for the drug Renastart for the indication: chronic renal failure in paediatric patients over 2 years of age.

Preparation of opinions on draft health policy programmes of local government units:

  • “Programme of early detection of colorectal cancer among residents of the Municipality of Pszczyna for 2023-2027”,
  • “Type 2 diabetes prevention programme for the residents of Pszczyna aged 45-65 for 2023-2027”.

Information on the previous agenda can be found HERE